Cargando…

Exploration of the Effects of TGF-β Pathway-Based Pituitary Tumor of Rats on GH3 Cell Line after Intervention with Different Concentrations of TGZ

The effect of the TGF-β pathway-based pituitary tumor of rats on the GH3 cell line after intervention with different concentrations of troglitazone (TGZ) is explored. The CH3 cell line of 24 clean male SD rats with pituitary adenoma is selected. The cells are divided into a blank contrast set and an...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Jiafeng, Hu, Chunmei, Zhang, Qiujuan, Zhu, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402356/
https://www.ncbi.nlm.nih.gov/pubmed/36072638
http://dx.doi.org/10.1155/2022/7445042
Descripción
Sumario:The effect of the TGF-β pathway-based pituitary tumor of rats on the GH3 cell line after intervention with different concentrations of troglitazone (TGZ) is explored. The CH3 cell line of 24 clean male SD rats with pituitary adenoma is selected. The cells are divided into a blank contrast set and an experimental set. The experimental set is divided into different TGZ concentration sets, including 1 × 10(−3) TGZ set, 1 × 10(−4) TGZ set, and 1 × 10(−5) TGZ set. The cell proliferation is detected by the CCK-8 method, the protein expressions of CD147, TGF-β1, and MMP-9 are detected by the western blot method, and the relative mRNA expressions of CD147, TGF-β1, and MMP-9 are detected by the qRT-PCR method. The expression levels of CD147, TGF-β1, and MMP-9 in CH3 cells of pituitary adenoma rats are notoriously lower, while the expression of CD147, TGF-31, and MMP-9 could be reduced by TGZ acting on the GH3 cell line. The specific mechanism of action of this effect on the invasive ability of GH3 cell lines is multifaceted, suggesting that peroxisome proliferator activator-receptor (PPAR-γ) agonists have good clinical application prospects in tumor therapy and can provide new targets and approaches for tumor drug therapy.